Skip to main content

Advertisement

SpringerLink
Log in

Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma

  • Original Article
  • Published:
Pediatric Surgery International Aims and scope Submit manuscript

Abstract

The prognosis of rhabdomyosarcoma (RMS) in advanced stages is still sobering. Therapy is limited due to local tumor recurrence, development of metastases and multidrug resistance. The aim of this study was to investigate the development of multidrug resistance in cell lines and in xenografts of alveolar and embryonal RMS treated according to the German Soft Tissue Sarcoma Study (CWS). Alveolar and embryonal RMS cell lines were treated with Vincristine, Topotecan, Carboplatin, Actinomycin D, or Ifosfamide. Expression levels of resistance-associated genes were assessed using Real time-PCR. Nude mice (NMRI nu/nu, n = 10 per group) underwent xenotransplantation of human embryonal or alveolar RMS. Animals were treated with standard chemotherapeutic drugs Vincristine, Topotecan, Carboplatin, Actinomycin D, or Ifosfamide according to treatment schedules of the CWS-study. Tumor sizes were measured and relative tumor volumes were calculated. Animals were sacrified after 20 days and standard histology, Real-time-PCR for MDR1-, MRP-, LRP- and MDM2-gene as well as immunhistochemistry for MDR1-, LRP-, and MRP-protein were performed. In the cell lines, an up-regulation of MDR-1 gene was found in alveolar rhabdomyosarcoma. In embryonal rhabdomyosarcoma, an up-regulation of LRP and MRP was found. Standard chemotherapy of alveolar rhabdomyosarcoma resulted in a significant reduction of tumor growth (P < 0.05) in all groups. In embryonal rhabdomyosarcoma strongest effects were found after treatment with Ifosfamide, Vincristine and Carboplatin (P < 0.05). RT-PCR revealed a MDR1-dependent mechanism in alveolar rhabdomyosarcoma. In embryonal rhabdomyosarcoma, MDR1 occurred to a lower degree. Immunhistochemistry revealed correlating expression levels of multidrug resistance-associated proteins. The use of established chemotherapy on human RMS in vivo had strong effects on xenografts compared to their controls. In all cases, there was only a reduction of tumor growth, but not a complete eradication of the tumors. Chemotherapy seemed to upregulate the expression of resistance-associated genes in vitro and in vivo. The mechanism of multidrug resistance depends on the tumor subtype. Therefore, further investigations will be required to evaluate multidrug resistance in patients and to investigate new modalities for a reversal of multidrug resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Fuchs J, Wenderoth M, von Schweinitz D, Haindl J, Leuschner I (1998) Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma. Cancer 83(11):2400–2407

    Article  PubMed  CAS  Google Scholar 

  2. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50:219–244

    PubMed  CAS  Google Scholar 

  3. Cocker HA, Pinkerton CR, Kelland LR (2000) Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines. Br J Cancer 83(3):338–345

    Article  PubMed  CAS  Google Scholar 

  4. Christ WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS (2001) Intergroup rhabdomyosarcoma study-IV: results of patients with non-metastatic disease. J Clin Oncol 19:3091–3102

    Google Scholar 

  5. Newton WA Jr, Gehan EA, Webber BL, Marsden HB, van Unnik AJ, Hamoudi AB, Tsokos MG, Shimada H, Harms D, Schmidt D (1995) Classification of rhabdomyosarcomas and related sarcomas. Cancer 76:1073–1085

    Article  PubMed  Google Scholar 

  6. Lawrence W Jr, Anderson JR, Gehan EA, Maurer H (1997) Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma study group. Children’s cancer study group. Pediatric oncology group. Cancer 80:1165–1170

    Article  PubMed  Google Scholar 

  7. Crist WM, Garnsey L, Beltangady MS, Gehan E, Ruyman F, Webber B, Hays DM, Wharam M, Maurer HM (1990) Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II intergroup rhabdomyosarcoma committee. J Clin Oncol 8:443–452

    PubMed  CAS  Google Scholar 

  8. Treuner J, Koscielniak E (2003) Cooperative Weichteilsarkomstudie CWS 2002-P. Study protocol

  9. Stevens MC, Rey A, Bouvet N, Ellershaw C, Flammant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the international society of paediatric oncology—SIOP malignant mesenchymal tumor 89. J Clin Oncol 23(12):2586–2587

    Google Scholar 

  10. Meza JL, Anderson J, Pappo AS, Meyer WH, Children’s oncology group (2006) Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the children’s oncology group. J Clin Oncol 24(24):3844–3851

    Article  PubMed  Google Scholar 

  11. Ferrari A, Casanova M, Bisogno G, Zanetti I, Cecchetto G, De Bernardi B, Riccardi R, Tamaro P, Meazza C, Alaggio R, Ninfo V, Carli M, Italian Cooperative Group (2003) Rhabdomyosarcoma in infants younger than one year old: a report from the italian cooperative group. Cancer 97(10):2597–2604

    Article  PubMed  Google Scholar 

  12. Warmann SW, Hunger M, Teichmann B, Flemming P, Gratz KF, Fuchs J (2002) The role of MDR1 gene in the development of multidrug resistance in human hepatoblastoma. Cancer 95(8):1795–1801

    Article  PubMed  CAS  Google Scholar 

  13. Chan HSL, Thorner PS, Haddad G, Ling V (1990) Immunohistochemical detection of P-glycoprotein—prognostic correlation in soft-tissue sarcoma of the childhood. J Clin Oncol 8:689–704

    PubMed  CAS  Google Scholar 

  14. De Cremoux P, Jourdan-Da-Silva N, Couturier J, Tran-Perennou C, Schleiermacher G, Fehlbaum P, Doz F, Mosseri V, Delattre O, Klijanienko J, Vielh P, Michon J (2006) Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer DOI 10.1002/pbc.20853

  15. Ramachandran C, Melnick SJ, Escalon E, Jhabvala P, Khatib Z, Alamo A, Smith S (2000) Expression of apoptosis, cell proliferation, and drug resistance genes in pediatric wilms’ tumors. Anticancer Res 20(5C):3759–3765

    PubMed  CAS  Google Scholar 

  16. Livak KJ, Schmittgen (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 −ΔΔCT method. Methods 25:402–408

    Article  PubMed  CAS  Google Scholar 

  17. Singer S, Demetri GD, Baldini EH, Fletcher CD (2000) Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 1:75–85

    Article  PubMed  CAS  Google Scholar 

  18. Hoffmann J, Schmidt-Peter P, Hänsch W, Naundorf H, Bunge A, Becker M, Fichtner I (1999) Anticancer drug sensitivity and expression of multidrug resistance markers in early passage of human sarcomas. Clin Cancer Res 90(7):788–793

    Google Scholar 

  19. Meco D, Colombo T, Ubezio P, Zucchetti M, Zaffaroni M, Riccardi A, Faircloth G, Jose J, D’Incalci M, Riccardi R (2003) Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 52:131–138

    Article  PubMed  CAS  Google Scholar 

  20. Thompson J, George O, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS, Ma M, Stewart CF, Houghton P (1999) Synergy of topotecan in combination with vincristin for treatment of pediatric solid tumor xenografts. Clin Cancer Res 5:3617–3631

    PubMed  CAS  Google Scholar 

  21. Koscielniak E, Morgan M, Treuner J (2002) Soft tissue sarcoma in children: prognosis and management. Paediatr Drugs 4(1):21–28

    PubMed  Google Scholar 

  22. Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ, Wiener ES, Maurer HM, Crist WM (2001) Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for intergroup rhabdomyosarcoma study V. J Pediatr Hematol Oncol 23(4):215–220

    Article  PubMed  CAS  Google Scholar 

  23. Cocker HA, Tiffin N, Pritchard-Jones K, Ross Pinkerton C, Kelland LR (2001) In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin Cancer Res 7:3193–3198

    PubMed  CAS  Google Scholar 

  24. Leuschner I, Heuer T, Harms D (2002) Induction of drug resistance in human rhabdomyosarcoma cell lines is associated with increased maturation: possible explanation for differentiation in recurrences? Pediatr Dev Pathol 5(3):276–282

    Article  PubMed  CAS  Google Scholar 

  25. Prados J, Melguizo C, Fernandez A, Aranega AE, Alvarez L, Aranega A (1996) Inverse expression of MDR1 and c-myc genes in a rhabdomyosarcoma cell line resistant to actinomycin D. J Pathol 180(1):85–89

    Article  PubMed  CAS  Google Scholar 

  26. Cowie FJ, Pritchard-Jones K, Renshaw J, Pinkerton CR (1998) Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines. Int J Oncol 12:1143–1149

    PubMed  CAS  Google Scholar 

  27. Komdeur R, Klunder J, van der Graaf WT, van der Berg E, de Bont ES, Hoekstra HJ, Molenaar WM (2003) Multidrug resistance proteins in rhabdomyosarcomas. Cancer 97(8):1999–2005

    Article  PubMed  Google Scholar 

  28. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P (1993) Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475–1479

    PubMed  CAS  Google Scholar 

  29. Klunder JW, Komdeur R, Van der Graaf WT, De Bont EJ, Hoekstra HJ, Van der Berg E, Molenaar WM (2003) Expression of multidrug resistance-associated proteins in rhabdomyosarcomas before and after chemotherapy: the relationship between lung resistance-related protein (LRP) and differentiation. Hum Pathol 34(2):150–155

    Article  PubMed  CAS  Google Scholar 

  30. Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, Houghton PJ, Harris LC (2000) P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol 35:96–103

    Article  PubMed  CAS  Google Scholar 

  31. Peng Y, Chen L, Li C, Lu W, Agrawal S, Chen J (2001) Stabilization of MDM2 oncoprotein by mutant p53. J Biol Chem 276:6874–6878

    Article  PubMed  CAS  Google Scholar 

  32. Cocker HA, Hobbs SM, Tiffin N, Pinkerton CR, Kelland LR (2001) High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br J Cancer 85(11):1746–1752

    Article  PubMed  CAS  Google Scholar 

  33. Ruymann FB, Grovas AC (2000) Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest 18(3):223–241

    PubMed  CAS  Google Scholar 

  34. Harms D (1995) Soft tissue sarcoma in the kiel pediatric tumor registry. In: Harms D, Schmidt D (eds) Current topics in pathology, soft tissue tumors, vol 89. Springer, Berlin Heidelberg New York, pp 31–45

  35. Melguizo C, Prados J, Fernandez JE, Velez C, Alvarez L, Aranega A (1994) Actinomycin D causes multidrug resistance and differentiation in a human rhabdomyosarcoma cell line. Cell Mol Biol 40(2):137–145

    PubMed  CAS  Google Scholar 

  36. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51(5):1417–1423

    PubMed  CAS  Google Scholar 

  37. Onisto M, Slongo ML, Gregnanin L, Gastaldi T, Carli M, Rosolen A (2005) Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 27(3):791–798

    PubMed  CAS  Google Scholar 

  38. Warmann SW, Heitmann H, Teichmann B, Gratz KF, Ruck P, Hunger M, Fuchs J (2005) Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma. Pediatr Hematol Oncol 22(5):373–386

    Article  PubMed  CAS  Google Scholar 

  39. Warmann S, Gohring S, Teichmann B, Geerlings H, Pietsch T, Fuchs J (2003) P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. Anticancer Res 23(6C):4607–4611

    PubMed  CAS  Google Scholar 

  40. Germann UA, Shlyakther D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J, Harding MW (1997) Cellular and biochemical characterization of VX-710 as a chemosensitizer; reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8:125–140

    Article  PubMed  CAS  Google Scholar 

  41. Ganjavi H, Gee M, Narendan A, Freedman MH, Malkin D (2005) Adenovirus-mediated p53 gene therapy in pediatric soft tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 12(4):397–406

    Article  PubMed  CAS  Google Scholar 

  42. Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Nev M, Crepaldi T, Ponzetto C (2006) Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcomas. Cancer Res 66(9):4742–4749

    Article  PubMed  CAS  Google Scholar 

  43. Wu H, Hait WN, Yang JM (2003) Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 63(7):1515–1519

    PubMed  CAS  Google Scholar 

  44. Lage H (2006) MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets 7(7):813–821

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Fortüne-Program of the Medical Faculty, University of Tuebingen, Germany (Grant: 1278-0-0).

Author information

Authors and Affiliations

  1. Department of Pediatric Surgery, University Children’s Hospital, Hoppe-Seyler-Strasse 1, 72076, Tuebingen, Germany

    Guido Seitz, Steven W. Warmann, Heike Heitmann, Claudia Treuner & Jörg Fuchs

  2. Department of Pathology, University Hospital, Michaelisstrasse 11, 24105, Kiel, Germany

    Christian O. Vokuhl & Ivo Leuschner

Authors
  1. Guido Seitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven W. Warmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian O. Vokuhl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Heike Heitmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claudia Treuner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ivo Leuschner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jörg Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guido Seitz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seitz, G., Warmann, S.W., Vokuhl, C.O. et al. Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma. Pediatr Surg Int 23, 431–439 (2007). https://doi.org/10.1007/s00383-006-1852-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00383-006-1852-z

Keywords

Search

Navigation